Smoking Cessation
Conditions
Brief summary
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
Interventions
DRUGSBP-9330
SBP-9330 oral capsules
DRUGPlacebo
Placebo oral capsules
Sponsors
National Institute on Drug Abuse (NIDA)
Sanford Burnham Prebys
University of California, San Diego
Camino Pharma, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of written informed consent prior to the initiation of any protocol-specific procedures 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Healthy male or female subject ≥ 18 and ≤ 55 years of age 4. Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 32.0 kg/m2 5. Body weight ≥ 50.0 kg at Screening 6. A female subject must meet at least one of the following criteria: a. Is of childbearing potential and agrees to use an acceptable contraceptive method. b. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e., at least 1 year without menses prior to the first study drug administration without an alternative medical condition and confirmed with a serum follicle-stimulating hormone \[FSH\] \> 40 IU/L at Screening) 7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from the first admission to the CRU until 90 days after the last study drug administration. 8. Part A and B only: Never- or nonsmoker (a nonsmoker is defined as someone who completely stopped using nicotine products for at least 2 years prior to the first study drug administration) 9. Have no clinically significant medical or mental health conditions captured in the medical history or evidence of clinically significant findings on the physical examination and/or ECG, as determined by an Investigator 10. No clinically significant abnormalities in blood pressure, heart rate, body temperature and respiratory rate and no evidence of orthostatic hypotension or postural tachycardia at Screening. Part C Only: 11. Are current tobacco cigarette smokers who smoke an average of 10 or more cigarettes per day in the 30 days prior to Screening 12. Expired breath CO level ≥10 parts per million (ppm) at Screening and prior to the first study drug administration 13. Positive test result for cotinine at Screening and prior to the first study drug administration 14. Are not motivated to try to quit smoking from Screening through 30 days from the first study drug administration
Exclusion criteria
1. Female who is lactating 2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration 3. Female who is planning to become pregnant during this study or within 90 days after the last study drug administration 4. Male with female partner who is pregnant, lactating, or planning to become pregnant during this study or within 90 days after the last study drug administration 5. Poor venous access as determined by an Investigator at Screening 6. History of significant hypersensitivity to SBP-9330 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs 7. Presence of any medical condition that, in the opinion of an Investigator, poses an unacceptable risk to the subjects 8. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug absorption 9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic, psychiatric (including mood and substance use disorders), neurological (including migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal, immunologic or dermatologic disease 10. History of malignancy within the past five years, except for successfully treated basal cell carcinoma of the skin 11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire administered at Screening 12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered at Screening 13. Routine or chronic use of more than three grams of acetaminophen daily 14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first) admission to the CRU 15. Current alcohol consumption exceeding two standard drinks per day on average (1 standard drink=10 grams of alcohol) for male subjects and one standard drink per day on average for female subjects 16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior to Screening 17. Any clinically significant illness in the 28 days prior to the first study drug administration 18. QTcF interval (QT interval corrected for heart rate according to Fridericia) \> 450 ms for males and \> 470 ms for females at Screening or on Day -1 19. Parts A and B only: Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration 20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody 21. Consumption of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) or over-the-counter medications and nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville \[blood\] orange products) or St. John's Wort within 14 days prior to the first study drug administration 22. Consumption of other prescription and over-the-counter medication not specifically excluded by Exclusion Criterion 21 including health supplements and herbal remedies within 7 days prior to the first study drug administration (an exception is made for paracetamol \[acetaminophen\], which is allowed up to admission to the clinic). 23. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data 24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is longer) prior to Screening 25. Inclusion in a previous cohort of this clinical study 26. Employee of the contract research organization (CRO) or the Sponsor. 27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening 28. Plasma donation within 7 days prior to Screening Part C Only: 29. History of generalized rash reaction to any drugs 30. Positive test result (except cotinine) for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration 31. Use of smoking cessation aids (NRT, bupropion, or varenicline) within 30 days prior to the first study drug administration 32. Unable to abstain from smoking tobacco cigarettes for at least 1 hour before and 2 hours after study drug administration 33. Unable to abstain from using nicotine-containing products other than tobacco cigarettes (e.g., pipes, cigars, e-cigarettes or vapes, nicotine topical patches, nicotine gum, or nicotine lozenges) during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | Part A: 8 days Part B: 21 days Part C: 21 days | Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of SBP-9330: Tmax | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Time to reach maximum observed concentration (Tmax) |
| Pharmacokinetics of SBP-9330: AUC 0-24 | PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose | Area under the concentration time curve from time 0 (dose administration) to 24 hours |
| Pharmacokinetics of SBP-9330: AUC 0-T | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration |
| Pharmacokinetics of SBP-9330: T½, Eff | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Effective half-life |
| Pharmacokinetics of SBP-9330: AUC 0-∞ | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Area under the concentration time curve extrapolated to infinity |
| Pharmacokinetics of SBP-9330: T½ | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Terminal elimination half-life |
| Pharmacokinetics of SBP-9330: CL/F | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Apparent total clearance |
| Pharmacokinetics of SBP-9330: Vz/F | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Apparent volume of distribution |
| Pharmacokinetics of SBP-9330: C Trough | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Observed concentration at the end of the dosing interval |
| Pharmacokinetics of SBP-9330: Cτ | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Concentration at the end of the dosing interval. |
| Pharmacokinetics of SBP-9330: AUCτ | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval) |
| Pharmacokinetics of SBP-9330: CL/Fss | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Apparent total clearance at steady state |
| Pharmacokinetics of SBP-9330: Vz/Fss | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Apparent volume of distribution at steady state |
| Pharmacokinetics of SBP-9330: RAC(Cmax) | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax |
| Pharmacokinetics of SBP-9330: RAC(AUC) | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Accumulation ratio evaluated by comparing Day 14 AUCτ to Day 1 AUC0-24 |
| Pharmacokinetics of SBP-9330: Cmax | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | Maximum observed concentration (Cmax) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Expired Carbon Monoxide (ECO) Level | Daily from Screening through Day 14 | Expired breath CO was measured with a Bedfont Smokerlyzer™ |
| Plasma Cotinine Level | Predose, Day 7 and Day 14 | Blood samples were collected to measure plasma cotinine levels |
| Number of Cigarettes Smoked | Daily from Screening through Day 14 | A daily smoking log was kept to document the number of cigarettes smoked |
| Minnesota Nicotine Withdrawal Scale (MNWS) | Screening through Day 14 | A self-report measure used to monitor symptoms of tobacco withdrawal. |
| Questionnaire on Smoking Urges - Brief Version (QSU-Brief) | Screening through Day 15 | A self-report questionnaire used to measure cravings to smoke. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Part A1 - Single-Dose (Active; 150 mg ) In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
SBP-9330: SBP-9330 oral capsules | 6 |
| Part A2 - Single-Dose Food-Effect (Active; 225 mg) In this two-period food-effect cohort, each healthy nonsmoker subject received the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects received the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
SBP-9330: SBP-9330 oral capsules | 6 |
| Part A3 - Single-Dose (Active; 300 mg) In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
SBP-9330: SBP-9330 oral capsules | 6 |
| Part A4 - Single-Dose (Active; 450 mg) In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
SBP-9330: SBP-9330 oral capsules | 6 |
| Part A5 - Single-Dose (Active; 600 mg) In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
SBP-9330: SBP-9330 oral capsules | 6 |
| Part A - Single Dose - Placebo (Pooled) In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects was randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
Placebo: Placebo oral capsules | 10 |
| Part B1 - Multiple-Dose (Active; 150 mg) In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
SBP-9330: SBP-9330 oral capsules | 8 |
| Part B2 - Multiple-Dose (Active; 225 mg) In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
SBP-9330: SBP-9330 oral capsules | 8 |
| Part B3 - Multiple-Dose (Active; 300 mg) In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
SBP-9330: SBP-9330 oral capsules | 8 |
| Part B - Multiple-Dose Placebo (Pooled) In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
Placebo: Placebo oral capsules | 6 |
| Part C1 - Smoker Phase (Active; 150 mg) In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
SBP-9330: SBP-9330 oral capsules | 8 |
| Part C2 - Smoker Phase (Active; 225 mg) In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
SBP-9330: SBP-9330 oral capsules | 8 |
| Part C - Smoker Phase Placebo (Pooled) In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
Placebo: Placebo oral capsules | 4 |
| Total | 90 |
Baseline characteristics
| Characteristic | Part A1 - Single-Dose (Active; 150 mg ) | Part A2 - Single-Dose Food-Effect (Active; 225 mg) | Part A3 - Single-Dose (Active; 300 mg) | Part A4 - Single-Dose (Active; 450 mg) | Part A5 - Single-Dose (Active; 600 mg) | Part A - Single Dose - Placebo (Pooled) | Part B1 - Multiple-Dose (Active; 150 mg) | Part B2 - Multiple-Dose (Active; 225 mg) | Part B3 - Multiple-Dose (Active; 300 mg) | Part B - Multiple-Dose Placebo (Pooled) | Part C1 - Smoker Phase (Active; 150 mg) | Part C2 - Smoker Phase (Active; 225 mg) | Part C - Smoker Phase Placebo (Pooled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 30.5 years STANDARD_DEVIATION 12.26 | 38.5 years STANDARD_DEVIATION 10.09 | 35.3 years STANDARD_DEVIATION 7.12 | 33.8 years STANDARD_DEVIATION 9.41 | 32.2 years STANDARD_DEVIATION 9.24 | 37.7 years STANDARD_DEVIATION 11.44 | 34.0 years STANDARD_DEVIATION 8.83 | 36.0 years STANDARD_DEVIATION 8.57 | 38.5 years STANDARD_DEVIATION 9.23 | 32.8 years STANDARD_DEVIATION 11.69 | 40.3 years STANDARD_DEVIATION 7.52 | 44.0 years STANDARD_DEVIATION 8.28 | 39.8 years STANDARD_DEVIATION 9.74 | 36.0 years STANDARD_DEVIATION 9.24 |
| Body mass index | 26.02 kg/m^2 STANDARD_DEVIATION 4.005 | 28.70 kg/m^2 STANDARD_DEVIATION 2.021 | 25.47 kg/m^2 STANDARD_DEVIATION 3.755 | 28.97 kg/m^2 STANDARD_DEVIATION 1.783 | 26.65 kg/m^2 STANDARD_DEVIATION 2.643 | 26.20 kg/m^2 STANDARD_DEVIATION 2.363 | 25.86 kg/m^2 STANDARD_DEVIATION 2.529 | 27.38 kg/m^2 STANDARD_DEVIATION 2.604 | 27.83 kg/m^2 STANDARD_DEVIATION 3.29 | 25.13 kg/m^2 STANDARD_DEVIATION 3.197 | 25.34 kg/m^2 STANDARD_DEVIATION 4.489 | 26.98 kg/m^2 STANDARD_DEVIATION 3.475 | 24.05 kg/m^2 STANDARD_DEVIATION 3.884 | 26.2 kg/m^2 STANDARD_DEVIATION 3.197 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 2 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 6 Participants | 6 Participants | 3 Participants | 4 Participants | 10 Participants | 5 Participants | 7 Participants | 8 Participants | 5 Participants | 8 Participants | 8 Participants | 3 Participants | 79 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 4 Participants | 4 Participants | 3 Participants | 4 Participants | 4 Participants | 2 Participants | 4 Participants | 1 Participants | 3 Participants | 3 Participants | 1 Participants | 2 Participants | 38 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) White | 3 Participants | 2 Participants | 2 Participants | 3 Participants | 1 Participants | 6 Participants | 4 Participants | 4 Participants | 6 Participants | 3 Participants | 2 Participants | 7 Participants | 2 Participants | 45 Participants |
| Region of Enrollment United States | 6 participants | 6 participants | 6 participants | 6 participants | 6 participants | 10 participants | 8 participants | 8 participants | 8 participants | 6 participants | 8 participants | 8 participants | 4 participants | 90 participants |
| Sex: Female, Male Female | 5 Participants | 3 Participants | 4 Participants | 0 Participants | 3 Participants | 3 Participants | 5 Participants | 3 Participants | 3 Participants | 0 Participants | 2 Participants | 3 Participants | 2 Participants | 36 Participants |
| Sex: Female, Male Male | 1 Participants | 3 Participants | 2 Participants | 6 Participants | 3 Participants | 7 Participants | 3 Participants | 5 Participants | 5 Participants | 6 Participants | 6 Participants | 5 Participants | 2 Participants | 54 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 6 | 0 / 8 | 0 / 8 | 0 / 4 |
| other Total, other adverse events | 0 / 6 | 2 / 6 | 1 / 6 | 1 / 6 | 1 / 6 | 3 / 10 | 8 / 8 | 7 / 8 | 8 / 8 | 5 / 6 | 6 / 8 | 8 / 8 | 1 / 4 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 6 | 0 / 8 | 0 / 8 | 0 / 4 |
Outcome results
Primary
Number of Treatment-Emergent Adverse Events [Safety and Tolerability]
Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results
Time frame: Part A: 8 days Part B: 21 days Part C: 21 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| A1 Single Dose (Active; 150 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 0 Participants |
| Part A2 - Single-Dose Food-Effect (Active; 225 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 Participants |
| Part A3 - Single-Dose (Active; 300 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 Participants |
| Part A4 - Single-Dose (Active; 450 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 Participants |
| Part A5 - Single-Dose (Active; 600 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 Participants |
| Part A - Single Dose - Placebo (Pooled) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 2 Participants |
| Part B1 - Multiple-Dose (Active; 150 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 7 Participants |
| Active Comparator: Part B2 - Multiple-Dose (Active; 225 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 4 Participants |
| Active Comparator: Part B3 - Multiple-Dose (Active; 300 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 5 Participants |
| Part B - Multiple-Dose Placebo (Pooled) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 4 Participants |
| Part C1 - Smoker Phase (Active; 150 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 4 Participants |
| Part C2 - Smoker Phase (Active; 225 mg) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 7 Participants |
| Part C - Smoker Phase Placebo (Pooled) | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 Participants |
Secondary
Pharmacokinetics of SBP-9330: AUC 0-∞
Area under the concentration time curve extrapolated to infinity
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: AUC 0-24
Area under the concentration time curve from time 0 (dose administration) to 24 hours
Time frame: PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: AUC 0-T
Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: AUCτ
Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval)
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: CL/F
Apparent total clearance
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: CL/Fss
Apparent total clearance at steady state
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: Cmax
Maximum observed concentration (Cmax)
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: C Trough
Observed concentration at the end of the dosing interval
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: Cτ
Concentration at the end of the dosing interval.
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: RAC(AUC)
Accumulation ratio evaluated by comparing Day 14 AUCτ to Day 1 AUC0-24
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: RAC(Cmax)
Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: T½
Terminal elimination half-life
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: T½, Eff
Effective half-life
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: Tmax
Time to reach maximum observed concentration (Tmax)
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: Vz/F
Apparent volume of distribution
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary
Pharmacokinetics of SBP-9330: Vz/Fss
Apparent volume of distribution at steady state
Time frame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Other Pre-specified
Expired Carbon Monoxide (ECO) Level
Expired breath CO was measured with a Bedfont Smokerlyzer™
Time frame: Daily from Screening through Day 14
Other Pre-specified
Minnesota Nicotine Withdrawal Scale (MNWS)
A self-report measure used to monitor symptoms of tobacco withdrawal.
Time frame: Screening through Day 14
Other Pre-specified
Number of Cigarettes Smoked
A daily smoking log was kept to document the number of cigarettes smoked
Time frame: Daily from Screening through Day 14
Other Pre-specified
Plasma Cotinine Level
Blood samples were collected to measure plasma cotinine levels
Time frame: Predose, Day 7 and Day 14
Other Pre-specified
Questionnaire on Smoking Urges - Brief Version (QSU-Brief)
A self-report questionnaire used to measure cravings to smoke.
Time frame: Screening through Day 15